We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies (AD3LE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02780011
Recruitment Status : Withdrawn (lack of funding)
First Posted : May 23, 2016
Last Update Posted : July 27, 2018
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
The Methodist Hospital Research Institute
Information provided by (Responsible Party):
Eric Bernicker, MD, The Methodist Hospital Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018